Twist Bioscience Corporation Common Stock (TWST) — Analysis Summary
Twist Bioscience Corporation Common Stock (TWST) has a market cap of $8.93B with year-over-year revenue growth of +20.3%. Net margin stands at -20.6%. The stock trades at a P/E ratio of -65.3.
Key Takeaways
- Revenue changed +20.3% year-over-year
- Net margin of -20.6%
- P/E ratio of -65.3
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, TWST posted revenue growth of +20.3% and trades at a P/E of -65.3.
Twist Bioscience Corporation Common Stock (TWST)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -33.6% — material operating losses
Net margin at -31.7% — significant losses
Net income fell 76.0% vs the prior period.
The latest filing shows negative free cash flow.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
979
Headquarters
SOUTH SAN FRANCISCO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.